Raymond James raised the firm’s price target on 89bio to $50 from $25 and keeps a Strong Buy rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ETNB:
- 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- 89bio Surges after Positive Topline Results
- 89bio price target raised to $45 from $34 at Cantor Fitzgerald
- 89bio NASH data show high statistical significance, says Cantor Fitzgerald
- 89bio’s pegozafermin trial statistically significant in critical histology